Another IL-17A/F Blocker Moves Forward for Psoriatic Arthritis

(MedPage Today) — A novel drug with the same mechanism as bimekizumab (Bimzelx), but in a smaller molecular package, met its main goals in a phase II study for psoriatic arthritis (PsA), paving the way for registration trials.
Called sonelokimab…